Questcor 'deceiving' the FDA, investors, Citron says Citron Research in a new blog post says Questcor is "deceiving" the FDA and investors. The short-selling blog claims Questor's H.P. Acthar Gel's active ingredient is less than 20% of the label specification. Shares of Questcor are down 1% to $60.94 following Citron's report. Reference Link
News For QCOR From The Last 14 Days
Check below for free stories on QCOR the last two weeks.